

1 **Title**

2 **Association between health-related hope and adherence to prescribed treatment in CKD**

3 **patients: multicenter cross-sectional study.**

4 **Running head:** Health-related hope and adherence in CKD

5

6 Noriaki Kurita, MD, PhD, FACP<sup>1,2,3</sup>, Takafumi Wakita, PhD<sup>4</sup>, Yoshitaka Ishibashi, MD, PhD<sup>5</sup>,

7 Shino Fujimoto, MSc<sup>5</sup>, Masahiko Yazawa, MD, PhD<sup>6</sup>, Tomo Suzuki, MD, PhD<sup>6,7</sup>, Kenichiro

8 Koitabashi, MD, PhD<sup>6</sup>, Mai Yanagi, MD<sup>5</sup>, Hiroo Kawarazaki, MD, PhD<sup>6,8</sup>, Joseph Green,

9 DMSc<sup>9</sup>, Shunichi Fukuhara, MD, DMSc, MACP<sup>2,10,11</sup>, Yugo Shibagaki, MD, PhD<sup>6</sup>.

10

11 Department of Innovative Research and Education for Clinicians and Trainees (DiRECT),

12 Fukushima Medical University Hospital, Fukushima, Japan<sup>1</sup>

13 Center for Innovative Research for Communities and Clinical Excellence (CIRC<sup>2</sup>LE),

14 Fukushima Medical University, Fukushima, Japan<sup>2</sup>

15 Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical

16 University, Fukushima, Japan<sup>3</sup>

17 Department of Sociology, Kansai University, Osaka, Japan<sup>4</sup>

18 Department of Nephrology, Japanese Red Cross Medical Center, Tokyo, Japan<sup>5</sup>

19 Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna

- 1 University School of Medicine, Kanagawa, Japan<sup>6</sup>
- 2 Department of Nephrology, Kameda Medical Center, Chiba, Japan<sup>7</sup>
- 3 Department of Nephrology, Inagi Municipal Hospital, Tokyo, Japan<sup>8</sup>
- 4 Graduate School of Medicine, The University of Tokyo, Tokyo, Japan<sup>9</sup>
- 5 Department of Healthcare Epidemiology, School of Public Health in the Graduate School of
- 6 Medicine, Kyoto University, Kyoto, Japan<sup>10</sup>
- 7 Section of Clinical Epidemiology, Department of Community Medicine, Graduate School of
- 8 Medicine, Kyoto University<sup>11</sup>

9

10 **Word count for the abstract:** 291 words

11 **Word count for the manuscript:** 3,242 words

12 **Short title:** hope and adherence in CKD

13

14 **Address correspondence to:** Noriaki Kurita, MD, PhD, FACP

15 Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical

16 University

17 1 Hikarigaoka, Fukushima City

18 Fukushima 960-1295, Japan

19 **TEL:** +81-24-547-1471

1 **FAX:** +81-24-547-1468

2 **E-mail:** [kuritanoriaki@gmail.com](mailto:kuritanoriaki@gmail.com)

3

4

5

6

1

## 2 **Abstract**

### 3 Background

4 In chronic kidney disease (CKD), patients' adherence to prescriptions for diet and for  
5 medications might depend on the degree to which they have hope that they will enjoy life, and  
6 that hope could vary with the stage of CKD. The aims of this study were to quantify both the  
7 association of CKD stage with health-related hope (HR-Hope), and the association of that  
8 hope with psychological and physiological manifestations of adherence.

9

### 10 Methods

11 This was a cross-sectional study involving 461 adult CKD patients, some of whom were  
12 receiving dialysis. Main exposure was HR-Hope, measured using a recently-developed  
13 18-item scale. Outcomes were perceived burden of fluid restriction and of diet restriction,  
14 measured using the KDQOL, and physiological manifestations of adherence (systolic and  
15 diastolic blood pressure [BP], and serum phosphorus and potassium levels).

16 General linear models and generalized ordered logit models were fit.

17

### 18 Results

19 Participants at non-dialysis stage 4 and those at stage 5 had lower HR-Hope scores than did

1 those at stage 2 or 3 (combined). Those at non-dialysis stage 5 had the lowest scores.  
2 HR-Hope scores of participants at stage 5D were similar to those of participants at stage 4,  
3 but they were lower than the scores of participants at stage 2 or 3 (combined). Higher  
4 HR-Hope scores were associated with lower perceived burdens of fluid restriction and of diet  
5 restriction (adjusted ORs per ten-point difference were 0.82 and 0.84, respectively). Higher  
6 HR-Hope scores were associated with lower systolic BP (adjusted mean difference in systolic  
7 BP per ten-point difference in HR-Hope scores was -1.87 mmHg). In contrast, HR-Hope  
8 scores were not associated with diastolic BP, serum phosphorus levels, or serum potassium  
9 levels.

10

## 11 Conclusions

12 Among CKD patients, HR-Hope is associated with disease stage, with psychological burden,  
13 and with some physiological manifestations of adherence.

14

15

## 16 **Keywords**

17 adherence; diet restriction; fluid restriction; chronic kidney disease; health-related hope

18

19

1

## 2 **Introduction**

3           In patients with chronic kidney disease (CKD), mortality and cardiovascular  
4 morbidity can be reduced. Specifically, they can be reduced if increases in blood pressure,  
5 retention of fluid, and excessive accumulation of salt, potassium, and phosphorus are  
6 prevented. Those goals can be achieved at least to some extent by adherence – both adherence  
7 to prescriptions for medication and adherence to prescribed restrictions on the intake of fluids  
8 and solid foods. (1, 2) Unfortunately, non-adherence appears to be quite common. (3) Results  
9 of a qualitative study indicate that both non-adherence to prescribed medication intake and  
10 non-adherence to prescribed fluid and dietary intake may be due in part to lack of motivation.  
11 (2) Research on other chronic diseases identified at least one important source of motivation  
12 for adherence: patients' hope. (4, 5)

13           Hope can be regarded as a goal-oriented way of thinking that enables people both to  
14 find routes toward their goals and also to sustain their motivation to pursue those goals. (6, 7)  
15 More than hope among healthy people, hope among patients with chronic illnesses is  
16 concerned with health. (8) For patients with CKD, it is possible that adherence to  
17 prescriptions for diet and medications can help them achieve their hoped-for goals. Thus,  
18 CKD patients with greater health-related hope may better cope with the burdens of adherence  
19 to those prescriptions, and as a result they might be better able to maintain relatively good

1 health. Despite this theoretical importance of hope in CKD patients, it has been studied only  
2 rarely. (9)

3 One analytical cross-sectional study of patients at CKD stage 5D showed that high  
4 scores on Snyder's hope scale were associated with a lower burden of kidney disease as  
5 measured using the KDQOL. (9) That study included only CKD patients who were  
6 undergoing dialysis. Their symptoms were not correlated with scores on Snyder's hope scale  
7 (which measures hope in general), but other likely correlates of hope, such as the severity of  
8 CKD and physiological manifestations of adherence to prescribed medications and diet, were  
9 not examined. (9) Patients' experiences of CKD vary with the stage of the disease: Patients  
10 who have some hope for enjoying life have a tendency to adjust to their condition, or to  
11 control it. (10) In this context, studies quantifying health-related hope, its relationships with  
12 patients' experiences at different stages of CKD, and its associations with physiological  
13 manifestations of adherence to prescribed medications and diet are likely to be clinically  
14 relevant. Specifically, such studies might help patients and clinicians develop interventions to  
15 increase hope and thereby promote adherence to those prescriptions.

16 To quantify the association of CKD stage with health-related hope, and the  
17 association of that hope with psychological and physiological manifestations of adherence to  
18 prescribed medications and diet, we used a recently developed scale to measure health-related  
19 hope (HR-Hope) (11) and we analyzed cross-sectional data from a prospective cohort study:

1 the HOpe Trajectory and Disease Outcome Consortium (HOTDOC) for Japanese patients  
2 with CKD.

3

#### 4 **Methods**

5 This was a multicenter cross-sectional study. The protocol was approved by the  
6 ethics review boards of the local health authorities.

7

8 Target population and settings

9 All of the participants were adults with CKD who were being treated by  
10 nephrologists. Some did not require dialysis, while others had CKD stage 5D and were  
11 receiving hemodialysis or peritoneal dialysis. Those with advanced cancer who were likely to  
12 die within one year and those with psychiatric disease or dementia were not included. The  
13 settings were one university hospital and four general hospitals. A total of 461 patients were  
14 registered between February 2016 and September 2017.

15

16 Study procedures.

17 Patients were asked to respond to the questionnaire after they gave informed consent.  
18 The questionnaire included the HR-Hope scale, and selected items from the Japanese version  
19 of the Kidney Disease Quality of Life (KDQOL) instrument.



1

2 Health-related hope scale (HR-Hope)

3           The HR-Hope scale measures hope among people with chronic diseases (Table S1  
4 and S2). (11) The items use a 4-point Likert-type scale: I don't feel that way at all, I feel that  
5 way a little, I feel that way somewhat, I strongly feel that way. The respondents are asked to  
6 "Please answer the questions below while keeping in mind how you feel about your future  
7 health prospects". Internal consistency reliability (coefficient alpha) was 0.93. Scores on the  
8 HR-Hope scale were moderately correlated with scores on both domains of Snyder's hope  
9 scale, (7, 12) and with scores on the 8 domains of the Medical Outcomes Study SF-36.(13) In  
10 addition, the HR-Hope scale was more sensitive to change in socio-clinical status than was  
11 Snyder's hope scale. For this study, the mean score of all 18 items was computed. For patients  
12 without family, the 2 items related to family were not applicable, thus the scale score was  
13 computed as the mean of the remaining 16 items. Next, the mean score was transformed to a 0  
14 – 100 score.

15

16 Exposures and outcomes: analytic framework

17           We examined how HR-Hope was associated with the psychological burden of CKD  
18 and with physiological manifestations of adherence that are applicable across all stages of  
19 kidney disease (see the conceptual framework in Fig. S1): (1-i) burden of fluid restriction,

1 (1-ii) burden of diet restriction, (2-i) systolic BP, (2-ii) diastolic BP, (3-i) serum phosphorus  
2 levels, and (3-ii) serum potassium levels. Abnormalities in serum phosphorus and potassium  
3 levels were taken as manifestations of non-adherence to prescribed diet. (14) Because  
4 excessive fluid and salt intake, and skipping prescribed doses of anti-hypertensive  
5 medications can contribute to BP elevation among CKD patients, abnormally high systolic  
6 and diastolic BPs were taken as manifestations of non-adherence to prescriptions for  
7 medications, fluid intake, and salt intake. Six categories of CKD were considered:  
8 non-dialysis stage 2/3, non-dialysis stage 4, non-dialysis stage 5, dialysis for 1 year or less,  
9 dialysis for >1 to 3 years, and dialysis for > 3 years. The perceived burdens of fluid restriction  
10 and diet restriction were assessed using items from the “Burden” subscale of the KDQOL.(15,  
11 16) Participants were asked "How much does kidney disease bother you in each of the  
12 following areas?" and the two areas considered were fluid restriction and dietary restriction.  
13 The response choices were "Not at all bothered", "Somewhat bothered", "Moderately  
14 bothered", "Very much bothered", and "Extremely bothered". Next, we examined whether  
15 HR-Hope was associated with the stage of CKD and with key socio-demographic factors (see  
16 the conceptual framework in Fig. S1).

17

18 Covariates

19 Covariates used in the analyses included socio-demographic characteristics (age,

1 gender, presence of family, and working status), primary renal disease, comorbidities  
2 (diabetes, coronary artery disease, and cerebrovascular disease), performance status (PS), and  
3 medication (type of phosphate binder, number of phosphate binders prescribed, prescription  
4 of potassium binder, class of antihypertensives prescribed, and total number of classes of  
5 antihypertensives). Presence of family was asked with the item "Do you have any family?"  
6 and the patients chose yes/no. Working status was asked using an item from KDQOL,(15, 16)  
7 in which the patients answered yes/no to "During the past 4 weeks, did you work at a paying  
8 job?". PS was assessed by the attending physician using scores developed by the Eastern  
9 Cooperative Oncology Group (Zubrod Scale). (17) Possible scores range from 0 (normal  
10 activity) to 4 (bedridden). A score of 2 (Ambulatory and capable of all self-care but unable to  
11 carry out any work activities. Up and about more than 50% of waking hours.) or higher was  
12 defined as impaired PS.

13

#### 14 *Data collection*

15 Medical data were collected from medical records by trained staff. Data on  
16 socio-demographic factors, primary renal disease, dialysis duration (only for patients  
17 receiving hemodialysis or peritoneal dialysis), comorbidities, medications, BP, and serum  
18 phosphorus and potassium were extracted from medical records written at the time when the  
19 participants received the questionnaires during their hospital visits. Among those receiving

1 hemodialysis, the data on BP and on serum phosphorus and potassium were those collected  
2 routinely, before the first dialysis session of each week (typically before starting dialysis on a  
3 Monday or a Tuesday).

4

#### 5 Statistical analysis

6 All statistical analyses were done using Stata/SE version 15 (Stata Corp., College  
7 Station, TX). Socio-demographic characteristics, comorbidities, laboratory data, and  
8 medication data were analyzed. The perceived burdens of fluid and diet restriction were  
9 analyzed using generalized ordered logit models, (18) with and without adjustment for key  
10 socio-demographic variables (adjusted model 1), and for variables in adjusted model 1  
11 together with primary renal disease and comorbidities (adjusted model 2). (18) For these  
12 analyses, the responses were collapsed into three categories: "Not at all bothered", "Somewhat  
13 or Moderately bothered", and "Very much or Extremely bothered", and odds ratios for  
14 increasing likelihood of degree of burden (at least "Somewhat or Moderately bothered" or at  
15 least "Very much or Extremely bothered") were estimated.

16 The analytic models for systolic and diastolic BP were general linear models, with  
17 and without adjustment for key socio-demographic variables (adjusted model 1), and for  
18 variables in adjusted model 1, primary renal disease, comorbidities, and the number of classes  
19 of prescribed antihypertensives (adjusted model 2). The analytic models for serum

1 phosphorus were general linear models, with and without adjustment for key  
2 socio-demographic variables (adjusted model 1), and for variables in adjusted model 1,  
3 primary renal disease, comorbidities, and the number of prescribed phosphate binders  
4 (adjusted model 2). The analytic models for serum potassium were general linear models,  
5 with and without adjustment for key socio-demographic variables (adjusted model 1), and for  
6 variables in adjusted model 1, primary renal disease, comorbidities, and prescription of  
7 potassium binders (adjusted model 2). The analytic models for HR-Hope were general linear  
8 models, with and without adjustment for key socio-demographic variables (adjusted model 1),  
9 and for variables in adjusted model 1 together with primary renal disease and comorbidities  
10 (adjusted model 2). Within each analysis, all problems of missing data on covariates were  
11 addressed by multiple imputation. (19) Five imputations were done using chained equations,  
12 with the assumption that the data were missing at random. P values < 0.05 were taken as  
13 indicators of statistical significance.

14

## 15 **Results**

### 16 **Participants**

17 Characteristics of the 461 participants are shown in Table 1. About 10.2% of the participants  
18 had impaired PS. Among the dialysis patients, about one third were receiving peritoneal  
19 dialysis (32%). Compared with the non-dialysis patients, the dialysis patients were younger,

1 and they were more likely to have diabetic nephropathy, impaired PS, and higher systolic BP  
2 and phosphorus levels. HR-Hope scores were normally distributed (Figure 1).

3

#### 4 Associations between HR-Hope and burdens

5 Figure 2 shows the distribution of perceived burden of fluid and dietary restrictions, by  
6 quartile-defined categories of HR-Hope scores. Both burdens were lower among participants  
7 with higher HR-Hope scores. Those associations were unchanged after adjustment for likely  
8 confounders (adjusted OR per ten-point difference 0.82, 95%CI 0.73 to 0.92 for fluid  
9 restriction, and 0.84, 95%CI 0.76 to 0.94 for dietary restriction, Table 2). Older participants  
10 perceived fluid restriction as being less burdensome than did younger participants (adjusted  
11 OR per ten-year difference 0.79, 95%CI 0.66 to 0.94). Employed participants perceived  
12 dietary restriction as being more burdensome than did non-employed participants (adjusted  
13 OR 1.88, 95%CI 1.20 to 2.94).

14

#### 15 Associations between HR-Hope and blood pressure

16 Participants with higher HR-Hope scores had lower systolic BP (mean difference per  
17 ten-point difference -1.9 mmHg, 95%CI -3.1 to -0.7) (Table S2, Fig. 3). In contrast,  
18 participants with higher HR-Hope scores had lower diastolic BP in the unadjusted analysis  
19 (mean difference per ten-point difference -0.9 mmHg, 95%CI -1.8 to -0.1), but not after

1 adjustment (mean difference per ten-point difference -0.6 mmHg, 95%CI -1.4 to 0.2).

2

3 Associations between HR-Hope and levels of phosphorus and potassium in serum

4 HR-Hope scores were not associated with the level of phosphorus or potassium in serum

5 (phosphorus: Table S4, Fig. 4A, potassium: Table S5, Fig. 4B).

6

7 Associations between disease stage and HR-Hope

8 HR-Hope scores were lower in participants at CKD stages 4 and 5 than in participants at CKD

9 stages 2 and 3 (Table 3, Fig. 5). After adjustment for likely confounders, being at a higher

10 stage of CKD was associated with having a lower HR-Hope score (Fig. 5; mean difference

11 -7.0 points, 95%CI -13.7 to -0.3 for stage 4, and -16.8 points, 95%CI -26.1 to -7.6, for stage

12 5). The difference in HR-Hope scores between participants at stage 4 and those at stage 2 or 3

13 was similar to the difference between participants who did and those who did not have family

14 (mean difference 7.7 points, 95%CI 2.3 – 13.1). The standardized effect sizes (Cohen's *d*) for

15 the differences between HR-Hope scores among participants at stage 4 and at stage 5 versus

16 those at stages 2 and 3 (combined), were 0.38 for stage 4 and 0.91 for stage 5. (20) Among

17 participants on dialysis, the HR-Hope scores were similar to the scores of those at stage 4, but

18 they were lower than the scores of those at stage 2 or 3. Participants who had been receiving

19 dialysis for 1 year or less had lower HR-Hope scores than did those at CKD stage 2 or 3

1 (mean difference -7.9 points, 95%CI -14.4 to -1.4). While the HR-Hope scores of participants  
2 who had been receiving dialysis for between 1 and 3 years were not lower than the scores of  
3 those who were at stage 2 or 3 (mean difference -4.9 points, 95%CI -11.3 to 1.6), participants  
4 who had been receiving dialysis for 3 years or longer had lower HR-Hope scores than did  
5 those at CKD stage 2 or 3 (mean difference -8.8, 95%CI -14.5 to -3.2).

6

7

## 8 **Discussion**

9 We found that HR-Hope was greater among those patients who reported that fluid  
10 restriction and dietary restriction were less burdensome. In addition, greater HR-Hope was  
11 associated with lower systolic BP. Finally, HR-Hope was associated with disease stage: hope  
12 was lowest among patients at non-dialysis stage 5, and it differed very little among the three  
13 groups defined by the duration of dialysis. These findings highlight the importance of  
14 integrating consideration of HR-Hope into clinical practice throughout the trajectory of CKD,  
15 to achieve better adherence to prescriptions for diet and medication.

16 These findings may be useful to researchers and clinicians in several ways. First, the  
17 finding that lower BP was associated with greater hope (as seen in the adjusted model for  
18 systolic BP and in the unadjusted model for diastolic BP) suggests that hopeful patients may  
19 more effectively adopt some self-management behaviors, resulting in better BP management.  
20 Specifically, that association may have resulted from less salt intake or better adherence to



1 prescriptions for antihypertensive agents, as hopeful patients might be more likely to develop  
2 strategies for dealing with their disease and for preventing it from worsening, both of which  
3 are measured using the HR-Hope scale (Question 10 and Question 11 in Table S1 and S2).  
4 Patients who have specific goals for their health may comprehend self-management behavior  
5 as way to achieve their goals and thus they may implement healthy behavior in their daily life.  
6 These notions are partially supported by the results of a previous study, which suggested that  
7 dialysis patients who feel benefits from salt restriction actually consume less salt,(21) and  
8 those who feel that they can control their health adhere more to prescriptions for medication.  
9 (22) Second, hope was not associated with the levels of phosphorus or potassium in serum.  
10 Because of the complexity of dietary management (knowledge about amounts of dietary  
11 phosphorus and potassium) and simultaneous considerations of family relationships and  
12 household income, (2, 23) choosing foods that contain only small amounts of phosphorus and  
13 potassium may be difficult. Family relationships can help to support healthy food choices and  
14 cooking, but can also interfere with patients' self-management. (2) Patients who were  
15 employed reported feeling a greater burden of dietary restrictions than did those who were not  
16 employed. This could reflect employed patients' difficulty in meal-related socializing. When  
17 they gather with work colleagues over lunch or dinner, which is important for maintaining  
18 business connections and work-group solidarity, (24) CKD patients may feel obliged to eat as  
19 other people do. (25) Third, HR-Hope is potentially modifiable by psychosocial interventions.

1 For example, individualized counseling can be aimed at increasing hope. In one study of  
2 hemodialysis patients, a well-organized, regular counseling program helped those patients to  
3 frame their hope during their illness and to find ways to reduce anxiety and stress. (26) Fourth,  
4 we found that hope was at its minimum among patients at stage 5 CKD, that is, among  
5 patients whose disease was so severe that they almost needed dialysis. Also, to the extent that  
6 a longitudinal trend can be inferred from data obtained cross-sectionally from patients who  
7 had undergone dialysis for different lengths of time (Figure 5), we found that hope was  
8 relatively stable over more than 3 years of dialysis therapy. Those two findings suggest that  
9 chronicity of disease course might also affect HR-Hope. As renal function deteriorates,  
10 HR-Hope might decrease because of anxiety and fear of an imminent lifelong dependence on  
11 dialysis, and of burdensome symptoms of uremia such as pulmonary edema, decreased  
12 appetite, malaise, and pruritus. While starting dialysis may alleviate symptoms of uremia,  
13 patients are forced to adjust their lives to their therapy (i.e. thrice-weekly visits to a dialysis  
14 center for those undergoing hemodialysis and every day at home for those undergoing  
15 peritoneal dialysis) and to a strict dietary and fluid-intake regimen, and thus they may have  
16 less HR-Hope than do patients who are still at stage 2 or 3 of CKD. Our observation that low  
17 levels of hope persist during the first 12 months of both hemodialysis and peritoneal dialysis  
18 concurs to some degree with previous studies focusing on 12-month change in health-related  
19 QOL of dialysis patients. (27, 28)

1           Several strengths of this study should be noted. First, we showed that HR-Hope is  
2 associated with objective manifestations of adherence to prescriptions for diet and  
3 medications. In contrast, a previous study of hope in general (not HR-Hope) found no  
4 association of hope with physical functioning or with symptoms and problems related to  
5 kidney disease. (9) Second, previously only hope in general had been studied (using Snyder's  
6 hope scale), and then only among patients at stage 5D.(9) In contrast, we found quantitative  
7 differences in HR-Hope across a wide range of severity-defined categories of CKD.

8           Several limitations of this study also warrant mention. First, because the study was  
9 cross-sectional, we cannot infer causal relationships from the associations of HR-Hope with  
10 the stage of kidney disease, or with objective manifestations of adherence. Patients with high  
11 systolic BP might struggle with the responsibility of taking multiple antihypertensive agents  
12 and following dietary instructions, and thus they might find fluid restriction and dietary  
13 restriction to be very burdensome, which might cause them to have little or no hope. Second,  
14 we were not able to quantify adherence itself by measuring, for example, intake of salt,  
15 phosphorus, and potassium, or by counting the numbers of prescribed doses of medications  
16 that patients did and did not take. Nonetheless, it may be argued that the objective indices we  
17 used are at least as important clinically as adherence itself. Third, HR-Hope may be affected  
18 by spiritual and religious factors. This could be important in some countries, but we believe  
19 that any effects it might have had on the differences we found in this study are negligible, as

1 all of the participants were Japanese, among whom few regularly engage in religious  
2 activities.

3

#### 4 **Conclusions**

5 Throughout the trajectory of CKD, HR-Hope changed with disease stage. It was  
6 lowest at non-dialysis stage 5, followed by stages 4 and 5D. Health-related hope was  
7 associated with the patient-perceived burden of fluid and dietary restriction, and also with  
8 some objective manifestations of adherence to prescriptions for diet and medications.

9 Therefore, nephrologists and dieticians should consider interventions for increasing HR-Hope  
10 to promote self-care and improve CKD patients' adherence to those prescriptions.

11

#### 12 **Declarations**

13 Ethics approval and consent to participate

14 This study was conducted in accordance with the Declaration of Helsinki. This study was  
15 approved by the ethics review boards of St. Marianna University School of Medicine  
16 (No.3209) and Fukushima Medical University (No.2417). Written consent was obtained.

17

18 Consent for publication

19 Not applicable.

1

2 Availability of data and materials

3 The datasets used and/or analyzed during the current study are available from the  
4 corresponding author on reasonable request.

5

6

7 Acknowledgements

8           The authors greatly thank the following researchers, research assistants, and medical  
9 staff members for their assistance in collecting the questionnaire-based and clinical  
10 information used in this study: Ms. Asako Tamura, Ms. Yuka Masuda, Ms. Takae Shimizu (St.  
11 Marriana University, Kawasaki-city, Kanagawa), Takayuki Nakamura, MD, Eiko Hashimoto,  
12 RN (JCHO Nihonmatsu Hospital, Nihonmatsu-city, Fukushima), Atsushi Kyan, MD, Masashi  
13 Saito, CE (Shirakawa Kosei General Hospital, Shirakawa-city, Fukushima), Ms. Lisa  
14 Shimokawa (Fukushima Medical University Hospital, Fukushima-city, Fukushima).

15

16

17 Competing interests

18 NK, TW, YI, S.Fujimoto, M. Yazawa, TS, KK, M. Yanagi, HK, JG, S.Fukuhara, and YS  
19 declare that they have no relevant financial interests.

1

2 Authors' contributions

3 Contributions: research idea and study design: NK, TW, YI, S. Fukuhara, YS; data

4 acquisition: NK, YI, S. Fujimoto, M Yazawa, TS, KK, M Yanagi, HK ; data analysis and

5 interpretation: NK, TW, YI, JG, S. Fukuhara, YS; statistical analysis: NK; supervision or

6 mentorship: YI, JG, S. Fukuhara, YS. Each author contributed important intellectual content

7 during article drafting or revision and accepts accountability for the overall work by ensuring

8 that questions pertaining to the accuracy or integrity of any portion of the work are

9 appropriately investigated and resolved.

10

11 Funding

12 This study was supported by JSPS KAKENHI (Grant Number: JP16H05216). The funders

13 had no role in the study design, analysis, or interpretation of data; writing of the manuscript;

14 or the decision to submit the manuscript for publication.

15

16

17 **References**

18 1. Kurita N, Hayashino Y, Yamazaki S, Akizawa T, Akiba T, Saito A, et al. Revisiting

19 Interdialytic Weight Gain and Mortality Association With Serum Albumin Interactions: The

- 1 Japanese Dialysis Outcomes and Practice Pattern Study. *Journal of Renal Nutrition*.
- 2 2017;27(6):421-9.
- 3 2. Palmer SC, Hanson CS, Craig JC, Strippoli GF, Ruospo M, Campbell K, et al.
- 4 Dietary and fluid restrictions in CKD: a thematic synthesis of patient views from qualitative
- 5 studies. *American journal of kidney diseases : the official journal of the National Kidney*
- 6 *Foundation*. 2015;65(4):559-73.
- 7 3. Saran R, Bragg-Gresham JL, Rayner HC, Goodkin DA, Keen ML, Van Dijk PC, et al.
- 8 Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice
- 9 patterns in the DOPPS. *Kidney international*. 2003;64(1):254-62.
- 10 4. Berg CJ, Rapoff MA, Snyder CR, Belmont JM. The relationship of children's hope to
- 11 pediatric asthma treatment adherence. *The Journal of Positive Psychology*. 2007;2(3):176-84.
- 12 5. Santos FR, Sigulem D, Areco KC, Gabbay MA, Dib SA, Bernardo V. Hope matters
- 13 to the glycemic control of adolescents and young adults with type 1 diabetes. *Journal of*
- 14 *Health Psychology*. 2015;20(5):681-9.
- 15 6. Buchanan CL, Lopez SJ. Understanding Hope in Individuals with Disabilities. In:
- 16 Wehmeyer ML, editor. *The Oxford Handbook of Positive Psychology and Disability*: Oxford
- 17 *University Press*; 2013. pp. 154-65.
- 18 7. Snyder CR, Harris C, Anderson JR, Holleran SA, Irving LM, Sigmon ST, et al. The
- 19 will and the ways: development and validation of an individual-differences measure of hope. *J*

- 1 Pers Soc Psychol. 1991;60(4):570-85.
- 2 8. Wakita T, Kurita N, Tominaga N, Kato K, Konno S, Fukuhara S, et al. Hope in Adult  
3 Patients with Chronic Disease: Qualitative Study. Kansai Univ Psychol Res. 2016(7):17-33  
4 (in Japanese except for English abstract).
- 5 9. Billington E, Simpson J, Unwin J, Bray D, Giles D. Does hope predict adjustment to  
6 end-stage renal failure and consequent dialysis? British Journal of Health Psychology.  
7 2008;13(4):683-99.
- 8 10. Teasdale EJ, Leydon G, Fraser S, Roderick P, Taal MW, Tonkin-Crine S. Patients'  
9 Experiences After CKD Diagnosis: A Meta-ethnographic Study and Systematic Review.  
10 American Journal of Kidney Diseases. 2017;70(5):656-65.
- 11 11. Fukuhara S, Kurita N, Wakita T, Green J, Shibagaki Y. A scale for measuring  
12 Health-Related Hope: its development and psychometric testing. Annals of Clinical  
13 Epidemiology. 2019;1(3):102-19.
- 14 12. Kato T, Snyder CR. The relationship between hope and subjective well-being:  
15 Reliability and validity of the dispositional Hope Scale, Japanese version. Jpn J Psychol.  
16 2005;76(3):227-34 (in Japanese).
- 17 13. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and  
18 validation of the SF-36 Health Survey for use in Japan. Journal of clinical epidemiology.  
19 1998;51(11):1037-44.



- 1 14. Denhaerynck K, Manhaeve D, Dobbels F, Garzoni D, Nolte C, De Geest S.  
2 Prevalence and consequences of nonadherence to hemodialysis regimens. *American Journal*  
3 *of Critical Care*. 2007;16(3):222-35.
- 4 15. Green J, Fukuhara S, Shinzato T, Miura Y, Wada S, Hays R, et al. Translation,  
5 cultural adaptation, and initial reliability and multitrait testing of the Kidney Disease Quality  
6 of Life instrument for use in Japan. *Quality of Life Research*. 2001;10(1):93-100.
- 7 16. Miura Y, Green J, Fukuhara S. *Manual of the KDQOL Japanese version 1.3*. Institute  
8 for Health Outcomes & Process Evaluation Research, Kyoto. 2004.
- 9 17. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al.  
10 Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol*.  
11 1982;5(6):649-56.
- 12 18. Williams R. Generalized ordered logit/partial proportional odds models for ordinal  
13 dependent variables. *Stata Journal*. 2006;6(1):58.
- 14 19. van der Heijden GJMG, T. Donders AR, Stijnen T, Moons KGM. Imputation of  
15 missing values is superior to complete case analysis and the missing-indicator method in  
16 multivariable diagnostic research: A clinical example. *Journal of clinical epidemiology*.  
17 2006;59(10):1102-9.
- 18 20. Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T.  
19 Estimating clinically significant differences in quality of life outcomes. *Quality of life*

- 1 research : an international journal of quality of life aspects of treatment, care and  
2 rehabilitation. 2005;14(2):285-95.
- 3 21. Agondi RdF, Gallani M-CBJ, Rodrigues RCM, Cornélio ME. Relationship Between  
4 Beliefs Regarding a Low Salt Diet in Chronic Renal Failure Patients on Dialysis. Journal of  
5 Renal Nutrition. 2011;21(2):160-8.
- 6 22. Theofilou P. Medication Adherence in Greek Hemodialysis Patients: The  
7 Contribution of Depression and Health Cognitions. International Journal of Behavioral  
8 Medicine. 2013;20(2):311-8.
- 9 23. Backman DR, Haddad EH, Lee JW, Johnston PK, Hodgkin GE. Psychosocial  
10 Predictors of Healthful Dietary Behavior in Adolescents. Journal of Nutrition Education and  
11 Behavior. 2002;34(4):184-93.
- 12 24. Lam LW, Twinn SF, Chan SWC. Self-reported adherence to a therapeutic regimen  
13 among patients undergoing continuous ambulatory peritoneal dialysis. Journal of Advanced  
14 Nursing. 2010;66(4):763-73.
- 15 25. Griva K, Ng HJ, Loei J, Mooppil N, McBain H, Newman SP. Managing treatment for  
16 end-stage renal disease – A qualitative study exploring cultural perspectives on facilitators and  
17 barriers to treatment adherence. Psychology & Health. 2013;28(1):13-29.
- 18 26. Rahimpour M, Shahgholian N, Yazdani M. Effect of hope therapy on depression,  
19 anxiety, and stress among the patients undergoing hemodialysis. Iranian journal of nursing

1 and midwifery research. 2015;20(6):694-9.

2 27. Broers NJH, Martens RJH, Canaud B, Cornelis T, DeJagere T, Diederren NMP, et al.

3 Health-related quality of life in end-stage renal disease patients: the effects of starting dialysis

4 in the first year after the transition period. *International Urology and Nephrology*.

5 2018;50(6):1131-42.

6 28. Lim HA, Yu Z, Kang AWC, Foo MWY, Griva K. The Course of Quality of Life in

7 Patients on Peritoneal Dialysis: A 12-month Prospective Observational Cohort Study.

8 *International Journal of Behavioral Medicine*. 2016;23(4):507-14.

9

10

1 **Table 1. Characteristics of analysis population**

	Non-dialysis Stage 2/3 n = 59	Non-dialysis Stage 4 n = 55	Non-dialysis Stage 5 n = 19	Dialysis 0 to 1 yr n = 66	Dialysis >1 to 3yr n = 72	Dialysis >3 yr n = 190	Total n = 461
<b>Dialysis modality, %<sup>a</sup></b>							
Hemodialysis				71.2%	52.8%	72.6%	68.0%
Peritoneal dialysis				28.8%	47.2%	27.4%	32.0%
<b>eGFR, mL/min/1.73 m<sup>2</sup></b>	46.1 (12.3)	22.4 (4.3)	11.5 (2.8)	6.9 (2.7)	5.0 (2.1)	4.0 (1.5)	12.5 (15.0)
<b>Age, yr</b>	70.7 (12.7)	74.5 (12.5)	73.9 (9.2)	66.8 (15.5)	64.9 (15.5)	64.3 (12.7)	67.2 (13.9)
<b>Women, %</b>	33.9%	30.9%	36.8%	27.3%	22.2%	36.3%	31.9%
<b>Renal disease, %</b>							
Diabetic nephropathy	5.1%	21.8%	15.8%	30.3%	43.1%	26.8%	26.0%
Glomerulonephritis	13.6%	12.7%	21.1%	25.8%	23.6%	34.2%	25.6%
Nephrosclerosis	37.3%	32.7%	31.6%	27.3%	15.3%	6.8%	19.1%
Polycystic kidney	0.0%	0.0%	5.3%	7.6%	1.4%	7.9%	4.8%
Others/Unknown	44.1%	32.7%	26.3%	9.1%	16.7%	24.2%	24.5%
<b>Impaired performance status, %</b>	1.7%	5.5%	5.3%	13.6%	6.9%	14.7%	10.2%
<b>Diabetes, %</b>	18.6%	45.5%	31.6%	43.9%	50.0%	33.2%	36.9%
<b>Cerebrovascular disease, %</b>	6.8%	16.4%	15.8%	16.7%	16.7%	12.1%	13.5%
<b>Coronary artery disease, %</b>	3.4%	23.6%	15.8%	16.7%	15.3%	16.8%	15.6%
<b>SBP, mmHg</b>	130 (17)	133 (17)	142 (20)	139 (22)	143 (24)	145 (28)	141 (25)
<i>Missing</i>	12	11	5		1		29
<b>DBP, mmHg</b>	79	69	72	75	75	79	77

	(12)	(14)	(12)	(15)	(15)	(17)	(16)
<i>Missing</i>	23	21	5		1		50
<b>Phosphorus, mg/dL</b>	3.2	3.6	4.0	5.3	5.4	5.5	5.0
	(0.4)	(0.5)	(0.7)	(1.5)	(1.3)	(1.4)	(1.5)
<i>Missing</i>	31	5				1	37
<b>Potassium, mEq/L</b>	4.4	4.8	4.7	4.4	4.4	4.7	4.6
	(0.3)	(0.6)	(0.5)	(0.7)	(0.7)	(0.8)	(0.7)
<i>Missing</i>	3					2	5
<b>N of categories of antihypertensive drugs, %</b>							
None	39.0%	14.6%	15.8%	21.2%	23.6%	38.4%	29.9%
1	33.9%	29.1%	26.3%	28.8%	23.6%	25.8%	27.3%
2	20.3%	32.7%	52.6%	31.8%	34.7%	21.1%	27.3%
3 or more	6.8%	23.6%	5.3%	18.2%	18.1%	14.7%	15.4%
<b>N of phosphate binder, %</b>							
None	100.0%	100.0%	89.5%	68.2%	30.6%	16.3%	49.7%
1 to 5	0.0%	0.0%	10.5%	18.2%	25.0%	19.5%	15.0%
6 to 10	0.0%	0.0%	0.0%	13.6%	27.8%	41.6%	23.4%
11 to 15	0.0%	0.0%	0.0%	0.0%	9.7%	15.8%	8.0%
16 or over	0.0%	0.0%	0.0%	0.0%	6.9%	6.8%	3.9%
<b>Prescription for potassium binder, %</b>	1.7%	16.4%	5.3%	3.0%	13.9%	23.7%	14.8%

1 For continuous variable, data were summarized as mean and standard deviation in parenthesis.

2 <sup>a</sup>Calculated only among dialysis patients.

3 eGFR: estimated glomerular filtration rate; SBP: systolic blood pressure; diastolic blood pressure

4

1 **Table 2. Associations between HR-Hope, key demographic factors, and degree of burdens of fluid or diet restriction.<sup>a</sup>**

	Fluid restriction (n = 444), OR (95% CI)			Diet restriction (n = 444), OR (95% CI)		
	Unadjusted	Adjusted 1 <sup>b</sup>	Adjusted 2 <sup>c</sup>	Unadjusted	Adjusted 1 <sup>b</sup>	Adjusted 2 <sup>c</sup>
<b>HR-Hope</b>						
<i>per 10 points</i>	<b>0.79</b> (0.71 – 0.87)	<b>0.83</b> (0.74 – 0.93)	<b>0.82</b> (0.73 – 0.92)	<b>0.84</b> (0.76 – 0.93)	<b>0.85</b> (0.77 – 0.95)	<b>0.84</b> (0.76 – 0.94)
<i>per 1 SD</i>	<b>0.65</b> (0.54 – 0.78)	<b>0.71</b> (0.58 – 0.87)	<b>0.69</b> (0.56 – 0.85)	<b>0.72</b> (0.60 – 0.87)	<b>0.74</b> (0.61 – 0.90)	<b>0.73</b> (0.60 – 0.89)
<b>Age, yr</b> <i>per 10 yr</i>	-	<b>0.80</b> (0.68 – 0.95)	<b>0.79</b> (0.66 – 0.94)	-	0.91 (0.78 – 1.06)	0.88 (0.75 – 1.03)
<b>Presence of family, yes</b>	-	0.96 (0.51 – 1.80)	1.02 (0.53 – 1.97)	-	1.12 (0.62 – 2.02)	1.16 (0.63 – 2.15)
<b>Working, yes</b>	-	1.11 (0.69 – 1.79)	1.13 (0.69 – 1.85)	-	<b>1.80</b> (1.16 – 2.79)	<b>1.88</b> (1.20 – 2.94)

2 <sup>a</sup>Generalized ordered logit models were used to estimate odds ratios for increasing degree of burdens.3 <sup>b</sup>Adjusted for age, gender, stage of renal disease, performance status, presence of family, and working status.4 <sup>c</sup>Adjusted for the covariates listed in footnote b, and also for primary renal disease, diabetes, coronary artery disease, and cerebrovascular disease.

5 HR-Hope: health-related hope; OR: odds ratio; 95% CI: 95% Confidence interval.

6

1 **Table 3. Associations between stage of kidney disease, key demographics, and levels of health-related hope.<sup>a</sup>**

	HR-Hope (n = 458), Mean difference, points (95% CI)		
	Unadjusted	Adjusted 1 <sup>b</sup>	Adjusted 2 <sup>c</sup>
<b>Stage of kidney disease</b> (vs. non-dialysis stage 2/3)	Ref.	Ref.	Ref.
<i>non-dialysis Stage 4</i>	<b>-7.1</b> (-13.8 – -0.4)	<b>-7.5</b> (-14.2 – -0.9)	<b>-7.0</b> (-13.7 – -0.3)
<i>non-dialysis Stage 5</i>	<b>-16.2</b> (-25.6 – -6.7)	<b>-17.2</b> (-26.5 – -8.0)	<b>-16.8</b> (-26.1 – -7.6)
<i>dialysis, &gt;0 to 1 yr</i>	<b>-11.8</b> (-18.3 – -5.4)	<b>-9.1</b> (-15.5 – -2.7)	<b>-7.9</b> (-14.4 – -1.4)
<i>dialysis, &gt;1 to 3 yr</i>	<b>-9.5</b> (-15.8 – -3.2)	<b>-6.6</b> (-12.9 – -0.3)	-4.9 (-11.3 – 1.6)
<i>dialysis, &gt;3 yr</i>	<b>-12.5</b> (-17.9 – -7.1)	<b>-10.1</b> (-15.5 – -4.6)	<b>-8.8</b> (-14.5 – -3.2)
<b>Age, yr</b> <i>per 10 yr</i>	-	<b>2.3</b> (1.0 – 3.7)	<b>2.1</b> (0.7 – 3.5)
<b>Presence of family, yes</b>	-	<b>7.5</b> (2.2 – 12.9)	<b>7.7</b> (2.3 – 13.1)
<b>Working, yes</b>	-	1.3	1.0

(-2.6 – 5.2)

(-2.9 – 4.9)

---

<sup>a</sup>General linear models were used to estimate mean differences in health-related hope scores.

<sup>b</sup>Adjusted for age, gender, stage of kidney disease, performance status, presence of family, and working status.

<sup>c</sup>Adjusted for the covariates listed in footnote b, and also for primary renal disease, diabetes, coronary artery disease, and cerebrovascular disease.

HR-Hope: health-related hope; 95% CI: 95% Confidence interval.

1  
2  
3  
4  
5  
6



1 **Legend to figures**

2

3 Figure 1. Distribution of HR-Hope scores

4

5 Figure 2. The distributions of degree of burdens of fluid or diet restriction by quartiles of  
6 HR-Hope score.

7 Figure 2A shows distributions of perceived burden of fluid restriction. Figure 2B shows  
8 distributions of perceived burden of diet restriction. Vertical axes indicate proportions of  
9 responses. Numbers in each bar graph indicate absolute numbers of responses (n = 444).

10 HR-Hope: health-related hope.

11

12 Figure 3. Associations between HR-Hope and blood pressure.

13 Red squares: unadjusted models. Blue circles: models adjusted for age, sex, performance  
14 status, presence of family, working status, and number of categories of prescribed  
15 antihypertensives (adjusted model 1). Green triangles: models adjusted for all of the variables  
16 listed above, and also for primary renal disease, diabetes, coronary artery disease, and  
17 cerebrovascular disease (adjusted model 2).

18

19 Mean differences estimated via general linear models (n = 429 for systolic BP and n = 408 for  
20 diastolic BP). Error bar indicate 95% confidence intervals.

21 HR-Hope: health-related hope; SBP: systolic blood pressure, DBP: diastolic blood pressure

22

23 Figure 4. Associations between HR-Hope and serum phosphorus or potassium levels.

24 Figure 4A: Association between HR-Hope and serum phosphorus. Red squares: unadjusted  
25 models. Blue circles: models adjusted for age, sex, performance status, presence of family,

1 working status, and number of categories of prescribed phosphate binders (adjusted model 1).  
2 Green triangles: models adjusted for all of the variables listed above, and also for primary  
3 renal disease, diabetes, coronary artery disease, and cerebrovascular disease (adjusted model  
4 2).

5 Figure 4B: Association between HR-Hope and serum potassium. Red squares: unadjusted  
6 models. Blue circles: models adjusted for age, sex, performance status, presence of family,  
7 working status, and number of categories of prescribed potassium binders (adjusted model 1).  
8 Green triangles: models adjusted for all of the variables listed above, and also for primary  
9 renal disease, diabetes, coronary artery disease, and cerebrovascular disease (adjusted model  
10 2).

11 Mean differences estimated via general linear models ( $n = 422$  for phosphorus and  $n = 453$  for  
12 potassium). Error bars indicate 95% confidence intervals.

13 HR-Hope: health-related hope; P: phosphorus, K: potassium

14

15 Figure 5. Association between stage of kidney disease and HR-Hope scores.

16 Red squares: unadjusted models. Blue circles: models adjusted for age, sex, performance  
17 status, presence of family, and working status (adjusted model 1). Green triangles: models  
18 adjusted for all of the variables listed above, and also for primary renal disease, diabetes,  
19 coronary artery disease, and cerebrovascular disease (adjusted model 2).

20 Vertical axis indicates mean difference in HR-Hope scores. Error bars indicate 95%  
21 confidence intervals. The stages of kidney disease shown here are non-dialysis stages 2 and 3  
22 (combined), which is the reference category, non-dialysis stage 4, non-dialysis stage 5, stage  
23 5D with dialysis duration no longer than 1 year, stage 5D with dialysis duration greater than 1  
24 but no longer than 3 years, and stage 5D with dialysis duration greater than 3 years.

25 Mean differences estimated via general linear models ( $n = 458$ ).

1 HR-Hope: health-related hope

2

3 **Titles of supplementary material**

4 Table S1. English version of the 18-item Health-Related Hope scale.

5 Table S2. Japanese version of the 18-item Health-Related Hope scale.

6 Figure S1. Conceptual framework used in regression analyses.


7 Table S3. The associations between HR-Hope and blood pressures.



8 Table S4. The associations between HR-Hope and serum phosphorus levels.


9 Table S5. The associations between HR-Hope and serum potassium levels

10


1 **Figure 1**



1 **Figure 2**2  
3

1 **Figure 3**

2

1 **Figure 4**

2

3

1 Figure 5

